[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"human-papilloma-virus-hpv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:human-papilloma-virus-hpv":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,71,99,125,148,170,199,223,245,341,368],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100632415","phase-2-omission-of-postoperative-radiation-in-hpv-associated-oropharyngeal-cancer-using-cthpvdna-surveillance-operation-100632415",false,"NCT07513389","Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)","Omission of Immediate Postoperative Radiation in Patients With Intermediate Pathological Risk Features and Negative Two-Week Post-Operative ctHPVDNA (OPERATION Trial)","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, ≥ 18 years of age (no upper age limit).\n* Biopsy proven squamous cell carcinoma.\n* p16 positive (diffuse ≥ 70% tumor cell expression, with at least moderate (2\u002F3+ staining intensity).\n* NavDx positive, HPV16 TTMV only.\n* AJCC 8th edition cT0-2 N1 M0.\n* Well lateralized tonsil (\\>1 cm from midline, tonsil, base of tongue, glossotonsillar sulcus primary tumors.\n* ≤ 2 lymph nodes, each ≤ 3cm, -OR- 1 lymph node \\>3 but \\\u003C 6 cm.\n* ≤10 pack-years of cigarette smoking or no cigarette smoking for ≥ 5 years (regardless of pack years).\n* Anatomically (e.g. adequate exposure) and physically amenable to TORS per the judgement of the operating surgeon.\n* Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to surgery; at a minimum CT imaging of the chest. PET\u002FCT is acceptable.\n* ECOG Performance Status 0-1.\n* CBC with differential obtained within 8 weeks prior to surgery, with adequate bone marrow function defined as follows:\n\n  * Platelets ≥ 100,000 cells\u002Fmm3\n  * Hemoglobin ≥ 9.0 g\u002Fdl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 9.0 g\u002Fdl is acceptable. Transfusion must be completed within 2 to 4 weeks prior to enrollment.)\n* Adequate renal and hepatic function within 8 weeks prior to surgery, defined as follows:\n\n  * Serum creatinine \\\u003C 2.0 mg\u002Fdl.\n  * Total bilirubin ≤ 1.5 x the institutional ULN.\n* Negative pregnancy test within 2 weeks prior to surgery for women of childbearing potential.\n* Eligible for platinum chemotherapy. Chemotherapy drugs allowed: cisplatin, carboplatin\u002Fpaclitaxel, carboplatin\u002Fabraxane, per treating physician (cisplatin preferred, 2nd preference carboplatin\u002Fpaclitaxel or carboplatin\u002Fabraxane).\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional year after surgery per MD discretion. Acceptable forms of birth control include hormonal contraceptives (such as birth control pills, skin patch, vaginal ring, injection, and\u002For implant), intrauterine devices (IUDs), and barrier devices (such as condoms, diaphragm, cervical cap, and sponge).\n\nExclusion Criteria:\n\n* Prior history of surgery to the head and neck that in the opinion of the investigators would modify prognostic significance of pathology results.\n* Prior history of radiation therapy to the head and neck, with the exception of skin cancer treated with a small (≤ 9cm3) field with 6 - 9 MeV electron beam or 50 - 250 kVp photon beam.\n* Prior history within 5 years of cancer with the exception of:\n\n  * Basal cell carcinoma of the skin\n  * Squamous cell carcinoma of the skin, stage 1-2\n  * Prostate cancer without distant metastases (stage M0)\n  * Thyroid cancer without distant metastases (stage M0)\n* Prior history of squamous cell carcinoma of a mucosal site in the head or neck treated with surgery alone.\n* Currently taking Disease Modifying Rheumatoid Drugs (DMRDs) or immunosuppressive medication, for example as for organ transplant or multiple sclerosis.\n* Current smoker or tobacco user.\n\n  * Severe, active co-morbidity, defined as one or more of the following:\n  * Unstable angina and\u002For congestive heart failure requiring inpatient hospitalization within the last 6 months.\n  * Transmural myocardial infarction within the last 6 months.\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.\n  * Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\n  * Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects.\n\n    \\--- Note, however, coagulation parameters are not required for entry into this protocol.\n  * Evidence of active systemic lupus or scleroderma.\n  * Psoriatic arthritis.\n* Known HIV positivity. HIV positive patients are known to have worse clinical outcomes especially for local, regional, and distant cancer control. This poorer prognosis is thought to be secondary to a compromised immune system. Thus, de-intensification of radiation and chemotherapy is not justifiable in this population.\n\n  \\-- Note: HIV testing at the time of enrollment is not required.\n* Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for the immediate post-op period (1-2 weeks). Females will be determined to be not of child-bearing potential with a history of hysterectomy or with postmenopausal status of \\>12 months.\n* Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study, starting one month prior to screening and for one year after surgery per MD discretion.\n* Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC). Eligible patients undergo transoral robotic surgery (TORS) and are observed without adjuvant radiation if they demonstrate low or intermediate pathological risk features and have negative circulating tumor HPV DNA (ctHPVDNA) two weeks post-operatively. Patients are followed with standard clinical surveillance combined with serial ctHPVDNA testing (NavDx®) to facilitate early detection of recurrence and prompt salvage therapy as needed.",[26,27,28],"Squamous Cell Carcinoma","Human Papilloma Virus (HPV)","Oropharyngeal Squamous Cell Carcinoma (OPSCC)","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":20},"2026-10-01",{"date":37,"type":20},"2030-07-01",{"name":39,"class":40},"Medical University of South Carolina","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100639976","phase-2-a-study-of-the-preliminary-efficacy-of-dare-hpv-to-treat-high-risk-persistent-human-papillomavirus-hrhpv-100639976","NCT07601074","A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)","A Phase 2a, Multi-Center, Placebo-Controlled, Double-Blinded, Randomized, Dose Ranging Study of the Preliminary Efficacy of DARE-HPV to Treat Persistent High-Risk Human Papillomavirus (HPV) Genital Infection","Inclusion Criteria:\n\n1. Provision of written informed consent prior to any study-specific procedures.\n2. Premenopausal women aged 22-50 years inclusive at the time of screening visit.\n3. Positive result for genital hrHPV (types 16, 18, or 'other') on at least 2 tests over the span of at least 12 months (history of persistent hrHPV infection for at least 12 months), based on review of participant's medical records. The visit 1 screening genital hrHPV test may be the second positive test.\n4. Generally, in good health with no clinically significant disease as determined by the Investigator.\n5. Regular menstrual cycle with an approximate 28-day cycle OR women who are amenorrheic due to effective contraception (such as levonorgestrel intrauterine system, or continuous oral contraception).\n6. Agree to refrain from vaginal douching, insertion of intravaginal devices (e.g., tampons, menstrual cups), and use of condoms for at least 48 hours before the first dose of study drug through at least 72 hours after the last dose of study drug.\n7. Agree to abstain from all vaginal and oral intercourse for at least 48 hours before the first dose of study drug through at least 72 hours after the last dose of study drug.\n8. Women at risk of pregnancy must use a highly effective form of birth control (confirmed by the Investigator) for the entire duration of the study. Rhythm methods and consistent use of condoms will not be considered as highly effective methods of birth control. Highly effective forms of birth control include:\n\n   * Heterosexual abstinence\n   * Vasectomized male partner (provided that the male partner is the sole sexual partner of the female participant with childbearing potential and that the vasectomized partner has received medical assessment of the surgical success);\n   * Oral or transdermal combined ethinyl estradiol\u002Fprogestin hormonal contraception associated with inhibition of ovulation;\n   * Oral, injectable or implantable progestogen-only hormone contraception associated with inhibition of ovulation (e.g., Depo-Provera™, Nexplanon, Slynd);\n   * Any effective copper intrauterine device\u002Flevonorgestrel intrauterine system;\n   * Female sterilization by tubal occlusion or bilateral salpingectomy;\n   * Supracervical hysterectomy.\n9. Ability and willingness to attend the necessary visits to the study center.\n10. Ability to comprehend all study related documentation, including written informed consent form, and complete all study-related tasks including daily diary.\n11. Be willing and able to adhere to the prohibitions and restrictions specified in the protocol.\n\nExclusion Criteria:\n\n1. Any significant disease or disorder (e.g., cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the results of the study, or the participant's ability to participate in the study.\n2. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening and at baseline, which in the opinion of the Investigator, may put the participant at risk because of her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.\n3. Cytological abnormality of the uterine cervix defined as LSIL or mild cervical intraepithelial neoplasia (CIN1), or HSIL or moderate (CIN 2) or severe (CIN 3) histology, as proven by cytology or colposcopic biopsy collected within the 12 months prior to screening or cytology at screening.\n4. Pregnant, breastfeeding, or lactating women (WOCBP must have a negative urine pregnancy test at screening and at the start of treatment \\[i.e., Day 1\\]).\n5. Active pelvic infection (positive for gonorrhea or chlamydial infection, positive test and symptoms for bacterial vaginosis, candida vaginitis or trichomonal vaginitis). Participants with positive results can be treated and re-tested once during screening.\n6. Positive result for hepatitis B, hepatitis C antibody or human immunodeficiency virus.\n7. Currently taking systemic immunosuppressants, biologics, intra-vaginal preparations, or any prescription that in the opinion of the Investigator could be a potential safety issue or interfere with the interpretation of the results.\n8. Previous exposure to lopinavir\u002Fritonavir (within 3 months prior to screening), contraindication to the use of lopinavir\u002Fritonavir or known allergy, hypersensitivity, or intolerance to any component of lopinavir\u002Fritonavir excipients.\n9. Recent history (within 3 months prior to screening) of Stevens-Johnson syndrome, erythema multiforme, urticaria, or angioedema.\n10. Receipt of any investigational product within 30 days or 5 half-lives prior to dosing.\n11. Participants who, in the opinion of the Investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular, the study restrictions and risks involved).","FEMALE","22 Years","50 Years",{"count":53,"type":20},118,[23],"The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.\n\nThe study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.",[27,57],"High-risk Human Papillomavirus Infection",[59,60],"HPV","hrHPV","NOT_YET_RECRUITING","2026-06-25",{"date":30,"type":33},{"date":65,"type":20},"2026-06",{"date":67,"type":20},"2027-12",{"name":69,"class":70},"Daré Bioscience, Inc.","INDUSTRY",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100643507","phase-3-cantharidin-application-in-patients-with-common-warts-verruca-vulgaris-cove-3-100643507","NCT07637734","Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)","COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102\u002FTO-208) in Subjects With Common Warts (Verruca Vulgaris)","COVE-3","Inclusion Criteria:\n\nCandidates will be included in the study if they:\n\n1. Are male or female patients ≥ 2 years of age.\n2. Are immunocompetent.\n3. Have a minimum of 1 treatable common wart (verruca vulgaris) of any size and height:\n\n   1. Common warts are considered treatable if they are located anywhere on the body, except for the following excluded areas: the eye area (including eyelids), lips, oral cavity, nasal cavity, inside of the ears, soles of the feet (plantar warts), subungual spaces (ie, under the fingernail or toenail), or the anogenital area (warts within 10 mm of a mucosal surface should not be treated).\n   2. Common warts located in excluded areas (warts within 10 mm of a mucosal surface) will not be treated or evaluated in this study. Warts that are genital, plantar, or anal are not considered common warts and are thus excluded from treatment and evaluation in this study. A subject will not be excluded from the study if they have these types of warts, but the subject must also have warts that meet the inclusion criteria. • If treatment of these excluded wart types is required during the study, it should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that are under study.\n4. Have no systemic or dermatologic disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.\n5. Agree to refrain from swimming, bathing, or prolonged immersion in water or any liquids until the study drug is removed after each treatment.\n6. Have the ability, or have a parent\u002Fguardian with the ability, to follow study instructions and the willingness to complete all study requirements.\n7. Agree not to use any wart-removing product (prescription or over-the-counter) other than the study drug during the course of the study, with the exception of circumstances allowed under Inclusion Criterion 3b.\n8. Provide written informed consent or assent in a manner approved by the IRB and\u002For have a parent\u002Fguardian provide written informed consent as evidenced by the signature on an IRB approved assent\u002Fconsent form. Subjects who turn 18 years of age (or legal age per state or country) during the study will be required to re-consent to remain on the study.\n9. Provide written authorization for use and disclosure of protected health information (per state and\u002For country requirements).\n10. If participating in the optional photographic assessment, agree to allow photographs of treatable common warts to be taken at selected visits by the research team.\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if they:\n\n1. Are unable to cooperate with the requirements or visits of the study, as determined by the Investigator.\n2. Have any warts present at Baseline in an allowed anatomic location that the subject, parent\u002Fguardian, or Investigator is unwilling to treat.\n3. Plantar warts and external genital warts will not be included in this study, in addition, subungual warts and warts within 10 mm of a mucosal surface will not be included in this study due to their anatomical location and complex treatment modalities.\n4. Are systemically immunosuppressed or have taken required systemic immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days before enrollment or such treatment is planned to be required during the course of the study. Routine use of local (eg, topical, inhaled, intranasal) corticosteroids and episodic use of systemic medications to treat conditions arising during the study is allowed.\n5. Have any chronic or acute medical condition that, in the opinion of the Investigator, may interfere with the study results or place the subject at undue risk (eg, human immunodeficiency virus, systemic lupus erythematosus, viral hepatitis, uncontrolled diabetes).\n6. Have had any previous treatment (including an investigational agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 30 days before treatment.\n7. Have more common warts, or wart area, to be treated than can be adequately covered with the contents of 2 study drug applicators, as determined by total wart surface area. Each applicator can cover approximately 1500 mm2 for a total of approximately 3000 mm2 using the 2 study drug applicators.\n8. Immunizations (eg, flu shots) may be administered throughout the study, but not within 5 days before or after any treatment with study drug and will be recorded as concomitant therapies in the eCRF.\n9. Have received any investigational product as part of a clinical trial NOT related to the treatment of common warts within 30 days before the first application of the study drug.\n10. Have epidermodysplasia verruciformis.\n11. Have an active malignancy or are undergoing treatment for any malignancy.\n12. Have a history or presence of clinically significant medical, psychiatric, or emotional condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data.\n13. Have a history or presence of hypersensitivity or an idiosyncratic reaction to the study drug or related compounds, or drug product excipients (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate).\n14. Have a condition or situation that may interfere significantly with the subject's participation in the study (eg, subjects who required hospitalization in the 2 months before screening for an acute or chronic condition including alcohol or drug abuse), as determined by the Investigator.\n15. Are sexually active or may become sexually active and are unwilling to practice a highly effective method of birth control (eg, combination of condoms and foam; oral contraceptives; intrauterine device with or without hormone release; transdermal, injectable, or intravaginal contraception). Withdrawal is not an acceptable method of birth control. Females who have reached menarche must have a negative urine pregnancy test at each visit before treatment with study drug.\n16. Are pregnant or breastfeeding.","2 Years",{"count":81,"type":20},300,[83],"PHASE3","This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \\[Cantharidin and Occlusion in Verruca Epithelium\\]) to evaluate the efficacy and safety of YCANTH (VP-102\u002FTO-208) treatment in subjects with common warts.",[86,87,27,88],"Common Warts","Common Warts (Verruca Vulgaris)","Warts",[86,87,27],"2026-06-09",{"date":92,"type":33},"2026-06-10",{"date":65,"type":20},{"date":95,"type":20},"2027-10",{"name":97,"class":70},"Verrica Pharmaceuticals Inc.",2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":49,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100579545","unidos-contra-el-vph-100579545","NCT06825689","Unidos Contra el VPH","Unidos Contra el VPH: Screening Preference and Uptake of HPV Self-sampling Among Latinxs Along the US-Mexico Border","Unidos","Inclusion Criteria:\n\n* Individuals with a cervix who are 30-65 years and have not undergone a Pap test in at least three years.\n\nExclusion Criteria:\n\n* Having had a hysterectomy or a personal history of cervical cancer.",true,"30 Years","65 Years",{"count":111,"type":20},735,[113],"NA","The purpose of the Unidos Contra el VPH study is to help find options to screen, or check, for cervical cancer that individuals can do at home to help prevent and detect cervical cancer early. Usually, people get screened for cervical cancer with a Pap smear and human papillomavirus (HPV) test by a health care provider. This is not always easy for individuals who are not able to get to a clinic or feel uncomfortable having the procedure done. That is why we want to find other ways that may be easier and more comfortable for people to be screened for cervical cancer.\n\nThe two main questions the study aims to answer are:\n\n1. How do the following three cervical cancer screening methods compare for improving screening completion rates?\n\n   o In-home HPV self-sampling with a vaginal swab\n   * In-home HPV self-sampling with urine testing\n   * In-clinic traditional Pap smear with HPV test\n2. What are participant beliefs and preferences regarding these three screening methods?\n\n   Participants in the study will be randomly assigned to one of three groups. This means each person has an equal chance of being placed in any group. They will also complete two surveys as part of the study. The three screening method groups are described below:\n\n   Group 1: Urine Self-Sampling\n   * Participants in this group will receive a kit with a urine sample cup to use at home, instructions explaining how to take the sample and a pre-paid mailing box to mail the urine sample to the lab.\n\n   Group 2: Vaginal Swab Self-Sampling o Participants in this group will receive a kit with a vaginal swab and collection tube to use at home, instructions explaining how to take the sample and a pre-paid mailing box to mail the sample to the lab.\n\n   Group 3: In-Clinic Screening\n   * An in-clinic co-testing appointment is scheduled for a Pap smear and HPV test done together at Project Vida Health Center.\n\n   By comparing these approaches, this study aims to improve access to cervical cancer screening and provide better options for those who face barriers to clinic-based screening.",[27,116],"Cervical Cancers","2026-06-08",{"date":92,"type":33},{"date":120,"type":33},"2025-01-28",{"date":122,"type":20},"2029-02",{"name":124,"class":40},"University of Texas at Austin",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},"100628152","phase-3-long-term-follow-up-study-of-cantharidin-ycanth-vp-102to-208-in-patients-with-common-warts-verruca-vulgaris-100628152","NCT07457918","Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102\u002FTO-208]) in Patients With Common Warts (Verruca Vulgaris)","COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCANTH (VP-102\u002FTO-208) in Subjects With Common Warts (Verruca Vulgaris)","COVE-4","Inclusion Criteria:\n\nCandidates will be included in the study if they:\n\n1. Meet ≥ 1 of the following criteria:\n\n   1. Completed the Day 84 visit in the parent study and have ≥ 1 treatable common warts.\n   2. Completed the Day 105 visit in the parent study and have ≥ 1 treatable common warts.\n   3. Completed the Day 147 visit in the parent study.\n2. Provide written informed consent or assent in a manner approved by the Institutional Review Board (IRB) and\u002For have a parent\u002Fguardian provide written informed consent as evidenced by the signature on an IRB approved assent\u002Fconsent form. Subjects who turn 18 years of age (or legal age per state or country) during the study may be required to re consent to remain on the study (follow the state or country regulatory requirements).\n3. Agree to refrain from swimming, bathing, or prolonged immersion in water or any liquids until the study drug is removed after each treatment.\n4. Have the ability, or have a parent\u002Fguardian with the ability, to follow study instructions and the willingness to complete all study requirements.\n5. Agree not to use any wart-removing product (prescription or over-the-counter) other than the study drug during the course of the study with the exception of circumstances for excluded wart types. Excluded warts include common warts located in excluded areas that will not be treated or evaluated during the study as well as genital, plantar, or anal warts:\n\n   a. If treatment of these excluded wart types is required during the study, it should be limited to destructive therapy such as cryosurgery and warts cannot be within 10mm of any warts that are under study.\n6. Provide written authorization for use and disclosure of protected health information (per state and\u002For country requirements).\n7. If participating in the optional photographic assessment, agree to allow photographs of treatable common warts to be taken at selected visits by the research team.\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if they:\n\n1. Are unable to cooperate with the requirements or visits of the study, as determined by the Investigator.\n2. Have any warts present at study entry in an allowed anatomic location that the subject, parent\u002Fguardian, or Investigator is unwilling to treat.\n3. Are systemically immunosuppressed or have taken required systemic immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days before enrollment or such treatment is planned to be required during the course of the study. Routine use of local (eg, topical, inhaled, intranasal) corticosteroids and episodic use of systemic medications to treat conditions arising during the study is allowed.\n4. Have any chronic or acute medical condition that, in the opinion of the Investigator, may interfere with the study results or place the subject at undue risk (eg, human immunodeficiency virus, systemic lupus erythematosus, viral hepatitis, uncontrolled diabetes).\n5. Have had any previous treatment (including an investigational agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 30 days before treatment.\n6. Immunizations (eg, flu shots) may be administered throughout the study, but not within 5 days before or after any treatment with study drug.\n7. Have received any investigational product as part of a clinical trial NOT related to the treatment of common warts within 30 days before the first application of the study drug.\n8. Have epidermodysplasia verruciformis.\n9. Have an active malignancy or are undergoing treatment for any malignancy.\n10. Have a clinically significant medical, psychiatric, emotional condition, or abnormality that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data.\n11. Have a hypersensitivity or an idiosyncratic reaction to YCANTH (VP-102\u002FTO-208) or related compounds, or drug product excipients (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate).\n12. Have a condition or situation that may interfere significantly with the subject's participation in the study (eg, subjects who require hospitalization for an acute or chronic condition including alcohol or drug abuse), at the determination of the Investigator.\n13. Are sexually active or may become sexually active and are unwilling to practice responsible birth control methods (eg., combination of condoms and foam, birth control pills, intrauterine device, patch, shot and vaginal ring). Withdrawal is not an acceptable method of birth control. Females who have reached menarche must have a negative urine pregnancy test at each visit before treatment with YCANTH (VP-102\u002FTO-208).\n14. Are pregnant or breastfeeding.",{"count":134,"type":20},600,[83],"People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are:\n\n* To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in Japan) by assessing concomitant medication use, and adverse events (AEs), including expected local skin reactions (LSRs).\n* To evaluate the efficacy of continued skin application of YCANTH (VP-102\u002FTO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments.\n\nParticipants with eligible common warts present will receive YCANTH (VP-102\u002FTO-208) with an interval of 21 (± 4) days between applications until there is a wart count of zero (ie, completed clearance has been achieved) or a maximum of 4 additional treatments. Participants with complete clearance will attend Observation Visits at intervals of 42 (± 4) days without treatment. Participants who develop a new wart after having a wart count of zero will resume Treatment Visits every 21 (± 4) days for a maximum of 4 additional treatments. All subjects will attend visits until the End-of-Study (EOS) Visit, which is on Day 378 (0\u002F+ 8 days).\n\nIf participants still have warts present after 4 additional treatments of YCANTH (VP-102\u002FTO-208) the wart(s) will be discontinued from study and participants will be allowed to seek treatment but should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that receive(d) study drug treatment . The exact interval of Treatment Visits will be determined by evaluation of the treatment site, taking into account any ongoing local skin reactions (LSRs), which are defined as temporary application site:\n\nvesiculation, pain, pruritus, scabbing, erythema, discoloration, dryness, edema and erosion that is expected and consistent with historical treatment with YCANTH (VP-102\u002FTO-208). Participants may receive treatment until all treatable common warts are clear, up to a maximum of 4 treatment sessions, or until Day 357, whichever occurs first.\n\nTreatment:\n\nFor participants with warts present at the time of study entry, the first treatment application may occur on the same day as transition from the parent study. All required parent study assessments must be complete, including the final evaluation of response to treatment (ERT; as defined in Assessments and procedures).\n\nIn addition, eligibility for participation in the LTFU study must have been determined, and informed consent\u002Fassent for participation in this LTFU study obtained. YCANTH (VP-102\u002FTO-208) will be applied by the Investigator or qualified member of the research team to treatable common warts, including an approximate 1 to 2 mm margin of healthy, surrounding skin. After YCANTH (VP-102\u002FTO- 208) is applied, warts are to be covered with occlusive tape (occlusive tape with similar properties should be used across all clinical sites) that will remain in place overnight and should be removed 24 hours after application of study drug and just before a 24-hour ERT. Before application of study drug, wart paring, if necessary, will be completed with a sharp surgical instrument (eg, scalpel or flexible medical blade) to remove any adherent thick scale from a treatable common wart. Wart paring is required to be performed at any treatment visit when adherent thick scale is present, and the Investigator feels paring can be safely performed. Paring should be conducted by a trained practitioner and in compliance with any local regulations and should be discontinued if it results in punctate bleeding or significant pain. Not all treatable common warts may require paring. If adherent scale is not present, study drug can be applied without paring. The assessment for complete clearance may be made once all treatable common warts are evaluable and not obscured by an ongoing LSR. If the Investigator is unable to evaluate or treat 1 or more warts due to ongoing LSRs, no warts should be treated, and the visit will be documented as an Unscheduled Visit. The timing of the next treatment visit will be determined by resolution of the LSRs. The research team will be in contact with the Participant until all LSRs are resolved. Once LSRs have resolved, a Treatment Visit will be scheduled within 21 (± 4) days of the previous treatment application, noting it may be longer than 21 (± 4) days depending on the length of time until LSR resolution. All treatable common warts that are not completely clear should undergo treatment with study drug. Study duration from Days 84, 105, or 147 of the parent study (COVE-2 or COVE-3) through the final EOS visit of this LTFU study (Day 378) is approximately 294 days.",[87,86,27,88],[87,86,27],"2026-04-30",{"date":141,"type":33},"2026-05-05",{"date":143,"type":33},"2026-03-11",{"date":145,"type":20},"2028-05-22",{"name":97,"class":70},4,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":156,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100634887","hpv-testing-as-a-prevention-of-cervical-dysplasia-and-cancer-before-planned-subtotal-hysterectomy-100634887","NCT07545525","HPV Testing as a Prevention of Cervical Dysplasia and Cancer Before Planned Subtotal Hysterectomy","HPV Testing as a Prevention of Cervical Dysplasia and Cervical Cancer Before Planned Subtotal Hysterectomy","Inclusion Criteria:\n\n* age over 18\n* indication for subtotal hysterectomy\n* consent to provide conisation in case the HPV test result is positive\n\nExclusion Criteria:\n\n* negative HPV test in the last 3 years",{"count":81,"type":20},"6 Months","OBSERVATIONAL","Patients indicated for subtotal hysterectomy will be tested for High risk HPV and if the result is positive will undergo expert colposcopy and conisation if not indicated otherwise at the time of subtotal hysterectomy",[160,27],"Cervical Cancer Screening","2026-04-21",{"date":163,"type":33},"2026-04-22",{"date":165,"type":20},"2026-04",{"date":167,"type":20},"2029-04",{"name":169,"class":40},"General University Hospital, Prague",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":49,"minAge":108,"maxAge":51,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":181,"conditions":182,"keywords":187,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100625933","early-phase-1-effectiveness-of-a-vaginal-gel-on-cin12-regression-and-hpv-clearance-100625933","NCT07429071","Effectiveness of a Vaginal Gel on CIN1\u002F2 Regression and HPV Clearance.","Effectiveness of a Non-Invasive Treatment Using a Vaginal Gel in Promoting HPV Clearance and Regression of Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Positive HPV test\n* Underwent colposcopy with subsequent histopathological findings of CIN1 or CIN2\n* Allocated to a 'watchful waiting' management strategy.\n* Understand Danish, written and orally.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Unexplained bleeding\n* Immunosuppressive\u002Fmodulatory diseases or treatment\n* Cancer or cancer related diseases",{"count":178,"type":20},70,[180],"EARLY_PHASE1","The goal of this clinical trial is to evaluate whether a Coriolus versicolor-based vaginal gel promotes regression of CIN1\u002FCIN2 and facilitates HPV clearance in women aged 30-50 years diagnosed with CIN1 or CIN2 and HPV. In addition, the study will assess patient satisfaction, treatment compliance and characterize the vaginal microbiome.\n\nThe primary outcomes therefore is:\n\n* the regression of the cervical dysplasia from baseline to the follow-up (6 months), which will be assessed through either liquid-based cytology and\u002For histopathology (biopsy).\n* HPV clearance from baseline to follow-up (6 months)\n\nIn this randomized controlled study, eligible participants will be randomized 1:1 into two groups:\n\n1. Intervention group: Women (n=35) will apply a CV-based vaginal gel (Papilocare®) daily for 21 days for 3 months. Afterward, the gel should be used every other day for an additional 3 months. Every month includes a 7-day break due to menstruation (28 days cycle).\n2. Control group; Women (n=35) will follow the conventional \"wait and see\" approach.",[183,184,185,186,27],"Womens Health","Cervical Dysplasia","Cervical Intraepithelial Neoplasia (CIN)","Non-invasive Treatment",[183,184,185,188,189],"Human Papillomavirus (HPV)","Non-Invasive Treatments","2026-03-02",{"date":192,"type":33},"2026-03-04",{"date":194,"type":20},"2026-03",{"date":196,"type":20},"2026-09",{"name":198,"class":40},"University of Aarhus",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":41},"100609438","using-plasma-human-papillomavirus-hpv-related-deoxyribonucleic-acid-dna-and-ribonucleic-acid-rna-to-follow-response-of-cervical-cancer-to-surgery-radiation-and-chemotherapy-100609438","NCT07214584","Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy","Inclusion Criteria:\n\n* 18 years and older\n* HPV-associated squamous cell, adenocarcinoma, or adenosquamous cancers of the uterine cervix with evaluable disease\n* Diagnosed with American Joint Committee on Cancer (AJCC) stage I or higher, or metastatic disease.\n* Presence of evaluable disease on pre-treatment standard of care imaging with plans to obtain serial post-treatment standard of care imaging\n* Agree to perform the required research-related blood tests and cervical mucous testing.\n\nExclusion Criteria:\n\n* Unable to consent or refusal to sign a consent form\n* Not meet any inclusion criteria\n* Unable to comply with follow up scheduling.\n* Diagnosed with a synchronous malignancy requiring cancer-directed therapy","89 Years",{"count":207,"type":20},55,"The goal of this study is to test two commercially available technologies for their ability to detect treatment response in patients with cervical cancer following surgery, radiation, and chemotherapy: one based on polymerase chain reaction (PCR; NavDx) and the other on branched DNA (Quantivirus HPV \\[DNA\\]). A 9-month feasibility study will be performed to examine the side-by-side utility of both NavDx and Quantivirus HPV DNA assays in predicting cervical cancer treatment response.\n\nThese tests could prove to be highly sensitive methods for evaluating minimal residual disease and for quantitation of response to surgery, radiation, and chemotherapy in patients with cervical cancer.\n\nPrimary Goal:\n\nFeasibility for NavDx HPV DNA assay (Naveris, Inc) to be used for personalized prediction of tumor response before and after treatment.\n\nSecondary Goals:\n\n1. Comparability of the Quantivirus HPV DNA\u002FmRNA assay (DiaCarta, Inc) with the NavDx HPV DNA assay and,\n2. Feasibility of the Quantivirus technology for measuring treatment response within the first day to 2 weeks of radiation, surgery, or a new chemotherapy.",[210,27],"Cervical Cancer",[59,212,210,213],"HPV Positive Cervical Cancer","Recurrent Cervical Cancer","2026-02-09",{"date":216,"type":33},"2026-02-12",{"date":218,"type":33},"2025-12-15",{"date":220,"type":20},"2026-12-31",{"name":222,"class":40},"University of Florida",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},"100611900","phase-3-cantharidin-application-in-patients-with-common-warts-verruca-vulgaris-cove-2-100611900","NCT07246590","Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)","COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris)","COVE-2","Inclusion Criteria:\n\nCandidates will be included in the study if they:\n\n1. Are male or female patients ≥ 2 years of age.\n2. Are immunocompetent.\n3. Have a minimum of 1 treatable common wart (verruca vulgaris) of any size and height:\n\n   1. Common warts are considered treatable if they are located anywhere on the body, except for the following excluded areas: the eye area (including eyelids), lips, oral cavity, nasal cavity, inside of the ears, soles of the feet (plantar warts), subungual spaces (ie, under the fingernail or toenail), or the anogenital area (warts within 10 mm of a mucosal surface should not be treated).\n   2. Common warts located in excluded areas (warts within 10 mm of a mucosal surface) will not be treated or evaluated in this study. Warts that are genital, plantar, or anal are not considered common warts and are thus excluded from treatment and evaluation in this study. A subject will not be excluded from the study if they have these types of warts, but the subject must also have warts that meet the inclusion criteria.\n\n      * If treatment of these excluded wart types is required during the study, it should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that are under study.\n4. Have no systemic or dermatologic disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.\n5. Agree to refrain from swimming, bathing, or prolonged immersion in water or any liquids until the study drug is removed after each treatment.\n6. Have the ability, or have a parent\u002Fguardian with the ability, to follow study instructions and the willingness to complete all study requirements.\n7. Agree not to use any wart-removing product (prescription or over-the-counter) other than the study drug during the course of the study, with the exception of circumstances allowed under Inclusion Criterion 3b.\n8. Provide written informed consent or assent in a manner approved by the IRB and\u002For have a parent\u002Fguardian provide written informed consent as evidenced by the signature on an IRB approved assent\u002Fconsent form. Subjects who turn 18 years of age (or legal age per state or country) during the study will be required to re-consent to remain on the study.\n9. Provide written authorization for use and disclosure of protected health information (per state and\u002For country requirements).\n10. If participating in the optional photographic assessment, agree to allow photographs of treatable common warts to be taken at selected visits by the research team.\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if they:\n\n1. Are unable to cooperate with the requirements or visits of the study, as determined by the Investigator.\n2. Have any warts present at Baseline in an allowed anatomic location that the subject, parent\u002Fguardian, or Investigator is unwilling to treat.\n3. Plantar warts and external genital warts will not be included in this study, in addition, subungual warts and warts within 10 mm of a mucosal surface will not be included in this study due to their anatomical location and complex treatment modalities.\n4. Are systemically immunosuppressed or have taken required systemic immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days before enrollment or such treatment is planned to be required during the course of the study. Routine use of local (eg, topical, inhaled, intranasal) corticosteroids and episodic use of systemic medications to treat conditions arising during the study is allowed.\n5. Have any chronic or acute medical condition that, in the opinion of the Investigator, may interfere with the study results or place the subject at undue risk (eg, human immunodeficiency virus, systemic lupus erythematosus, viral hepatitis, uncontrolled diabetes).\n6. Have had any previous treatment (including an investigational agent in a clinical trial) of common warts, including but not limited to the use of cantharidin, imiquimod, antivirals, retinoids, topical salicylic acid, lactic acid, hydrogen peroxide, trichloroacetic acid, pulse dye laser, iodine-based or nitric oxide-based therapies, oral cimetidine, coix seed, intralesional immunotherapy, curettage, or freezing of warts in the 90 days before treatment.\n7. Have more common warts, or wart area, to be treated than can be adequately covered with the contents of 2 study drug applicators, as determined by total wart surface area. Each applicator can cover approximately 1500 mm2 for a total of approximately 3000 mm2 using the 2 study drug applicators.\n8. Immunizations (eg, flu shots) may be administered throughout the study, but not within 5 days before or after any treatment with study drug and will be recorded as concomitant therapies in the eCRF.\n9. Have received any investigational product as part of a clinical trial NOT related to the treatment of common warts within 30 days before the first application of the study drug.\n10. Have epidermodysplasia verruciformis.\n11. Have an active malignancy or are undergoing treatment for any malignancy.\n12. Have a history or presence of clinically significant medical, psychiatric, or emotional condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data.\n13. Have a history or presence of hypersensitivity or an idiosyncratic reaction to the study drug or related compounds, or drug product excipients (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate).\n14. Have a condition or situation that may interfere significantly with the subject's participation in the study (eg, subjects who required hospitalization in the 2 months before screening for an acute or chronic condition including alcohol or drug abuse), as determined by the Investigator.\n15. Are sexually active or may become sexually active and are unwilling to practice a highly effective method of birth control (eg, combination of condoms and foam; oral contraceptives; intrauterine device with or without hormone release; transdermal, injectable, or intravaginal contraception). Withdrawal is not an acceptable method of birth control. Females who have reached menarche must have a negative urine pregnancy test at each visit before treatment with study drug.\n16. Are pregnant or breastfeeding.",{"count":81,"type":20},[83],"This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \\[Cantharidin and Occlusion in Verruca Epithelium\\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.",[86,87,27,88],[86,87,27],"2026-01-19",{"date":238,"type":33},"2026-01-21",{"date":240,"type":33},"2025-12-17",{"date":242,"type":20},"2027-06",{"name":97,"class":70},6,{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":107,"sex":16,"minAge":79,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":255,"conditions":256,"keywords":314,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":41},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","75 Years",{"count":254,"type":20},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,27,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","2026-01-14",{"date":334,"type":33},"2026-01-22",{"date":336,"type":33},"2025-12-18",{"date":338,"type":20},"2027-09-30",{"name":340,"class":40},"Institut Pasteur du Cambodge",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":59,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":4},"100608907","knowledge-and-beliefs-of-hearing-impaired-individuals-regarding-human-papillomavirus-hpv-100608907","NCT07207655","Knowledge and Beliefs of Hearing Impaired Individuals Regarding Human Papillomavirus (HPV)","The Effect of Card Game Education on the Knowledge and Health Beliefs of Hearing Impaired Individuals About Human Papillomavirus (HPV): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Participating in the study voluntarily\n* Being hearing impaired\n* Knowing sign language\n* Being a native Turkish speaker\n* Being over 18 years of age\n\nExclusion Criteria:\n\n* Having a disability other than hearing loss\n* Not knowing sign language\n* Having a psychiatric illness","60 Years",{"count":350,"type":20},40,[113],"Health education is one approach to influencing individuals, groups, or communities to achieve better health. The literature indicates that increasing awareness of HPV, along with participation in early screening and vaccination programs, can positively influence attitudes and behaviors. Therefore, this research will be conducted to determine the effect of education using the card game method on the knowledge and health beliefs of hearing-impaired individuals regarding Human Papilloma Virus (HPV).",[27,354],"Hearing Disability",[59,356,357,358],"Hearing impaired individual","health belief","health belief, information","2025-09-27",{"date":361,"type":33},"2025-10-06",{"date":363,"type":20},"2025-09-28",{"date":365,"type":20},"2025-12-31",{"name":367,"class":40},"Çankırı Karatekin University",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":107,"sex":16,"minAge":375,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":379,"conditions":380,"keywords":386,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":98},"100595727","transmission-of-oncogenic-hpv-infection-among-families-100595727","NCT07036211","Transmission of Oncogenic HPV Infection Among Families","TREVINO","Inclusion Criteria:\n\n* Patient with colposcopy clinic detected persisting HR-HPV infection\n* Patient with diagnosed cervical cancer\n* Patient with diagnosed OSCC\n* Patients' sexual partners of women or men that are referred to the colposcopy\u002Fgynecological oncology\u002FENT\n* offspring (over 12 years old) of the referred couples\n\nExclusion Criteria:\n\n* Candidate who don't speak Finnish","12 Years","100 Years",{"count":378,"type":20},700,"The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families. The research focuses on transmission between sexual partners and between parents and children. It also examines how the various microbes may influence the persistence of HPV infections and the development of HPV-related cancers.\n\nThe study will include up to 300 couples recruited from gynecology and ear, nose, and throat (ENT) clinics in Finland, as well as their children. Participants include individuals with persistent HPV infection, cervical precancer or cancer, or HPV-related head and neck cancer, along with their partners and potentially their offspring.\n\nParticipants will provide self-collected samples from the oral and genital areas at multiple time points over up to five years. Questionnaires addressing medical, behavioural, and environmental factors will be completed.\n\nThe study is conducted at Tampere University Hospital and Kuopio University Hospital in Finland. Results will inform HPV screening and prevention programs, improve understanding of family-level transmission, and identify potential microbial and genetic markers linked to cancer risk.",[27,381,382,383,384,385],"Cervical Carcinoma","Oropharyngeal Carcinoma","Transmission Vertical","Transmission","Human Papillomavirus Infection",[387,388,59],"Oropharyngeal cancer","Cervical cancer","2025-06-16",{"date":391,"type":33},"2025-06-25",{"date":393,"type":20},"2025-08",{"date":395,"type":20},"2031-12",{"name":397,"class":40},"Tampere University Hospital"]